At PEAR, we are focused on the development of prescription digital therapeutics to treat diseases with high unmet medical need.

PEAR is a fully integrated, prescription digital therapeutics company

We are developing software-based, prescription digital therapeutics designed to treat severe medical conditions. PEAR is seeking FDA clearance for these products. Our development process examines the clinical impact of these interventions in randomized clinical trials. We strive to provide enhanced outcomes for patients, supportive engagement and tracking tools for clinicians, and cost-effective solutions for payers.

Pear PipelinePEAR is also working on Generalized Anxiety Disorder (GAD), post-surgical pain, Major Depressive Disorder (MDD), and insomnia, among other indications.

PEAR’s lead products, reSET® and reSET-O™ have been evaluated in 6 randomized clinical trials involving over 1500 patients.*

In a clinical trial involving patients diagnosed with Substance Use Disorder (SUD), reSET® nearly doubled the rate of abstinence and increased retention in treatment compared to standard face-to-face therapy.*

Clinical trials have been completed to support the use of reSET-O in the treatment of Opiate Use Disorder (OUD) when used in conjunction with opioid replacement therapies.

THRIVE™ has been examined in three clinical studies involving 1,279 patients. Efficacy has been demonstrated as assessed by PANSS (the aggregate approvable endpoint for schizophrenia therapies) and patient engagement has been demonstrated beyond six months.


* Therapeutic Education System (TES), which has equivalent content to reSET®, was tested. Please see labeling for study details.